Loading clinical trials...
Loading clinical trials...
A Phase 3 Japanese Study of BMS-790052 Plus BMS-650032 Combination Therapy in Chronic Hepatitis C Genotype 1b Infected Subjects Who Are Non Response to Interferon Plus Ribavirin and Interferon Based Therapy Ineligible Naive/Intolerant
Conditions
Interventions
BMS-790052 (Daclatasvir)
BMS-650032 (Asunaprevir)
Locations
24
Japan
Local Institution
Nagoya, Aichi-ken, Japan
Local Institution
Chiba, Chiba, Japan
Local Institution
Fukuoka, Fukuoka, Japan
Local Institution
Kurume, Fukuoka, Japan
Local Institution
Ogaki-shi, Gifu, Japan
Local Institution
Hiroshima, Hiroshima, Japan
Start Date
January 1, 2012
Primary Completion Date
April 1, 2013
Completion Date
June 1, 2013
Last Updated
October 9, 2015
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions